RecruitingPhase 1NCT07160400

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity

Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)

Enrollment

104 participants

Start Date

Sep 4, 2025

Study Type

INTERVENTIONAL

Conditions

Part A: Healthy Part B: Overweight or Obesity

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI3032 tablets and a drug called Placebo for people with part a: healthy part b: overweight or obesity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Single dose placebo IBI3032 administered orally

DRUGIBI3032 tablets

Single dose of IBI3032 administered orally

Locations(1)

Zhongshan Hospital affiliated to Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07160400